导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.02% | 1964/4773 |
| 近一周 | -3.19% | 3855/5462 |
| 近一月 | -10.09% | 4965/5421 |
| 近一季 | -18.89% | 4769/5209 |
| 近半年 | -1.70% | 1666/4920 |
| 近一年 | 5.43% | 1598/4366 |
| 近两年 | 107.36% | 517/2954 |
| 近三年 | 61.50% | 422/2253 |
| 成立以来 | 79.50% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.08% 2106/4961 |
34.95% 936/5312 |
- - |
- - |
| 2025 | 48.46% 525/4813 |
-1.88% 2806/3635 |
2.98% 1223/4076 |
48.44% 374/4524 |
-1.02% 2786/4813 |
| 2024 | 13.92% 1093/3463 |
-4.29% 1632/2808 |
-6.22% 1887/3014 |
26.48% 260/3129 |
0.35% 1224/3463 |
| 2023 | -18.49% 1809/2656 |
1.91% 1485/2280 |
-6.91% 1738/2385 |
-9.03% 1769/2515 |
-5.55% 1394/2655 |
| 2022 | -28.35% 1550/2207 |
-19.31% 1444/1919 |
5.33% 918/2016 |
-17.42% 1592/2113 |
2.10% 1039/2208 |
| 2021 | 10.89% 413/1822 |
-6.89% 1044/1255 |
24.75% 106/1330 |
-6.61% 967/1466 |
2.22% 654/1822 |
| 2020 | 58.69% 134/1250 |
2.64% 130/1028 |
28.48% 102/1067 |
5.46% 918/1164 |
14.11% 297/1184 |
| 2019 | 38.12% 317/1092 |
30.46% 246/739 |
-9.32% 646/788 |
6.93% 108/850 |
9.18% 248/918 |
| 2018 | -25.37% 350/834 |
- - |
-13.53% 449/631 |
-10.78% 548/660 |
-10.32% 190/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发创业板ETF发起式联接A VS. 长安沪深300非周期A(740101) |